Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 33 AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 33 AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides a source of carbohydrates for caloric support; sodium chloride and potassium chloride provide electrolytes for maintenance of fluid and electrolyte balance. Potassium is essential for nerve conduction, muscle contraction, and acid-base balance.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion: 500-1000 mL over 2-6 hours, rate dependent on fluid and electrolyte status; typical maintenance: 1-2 mL/kg/hour.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Glucose: ~1-2 hours (rapid clearance). Sodium and potassium: no true half-life; regulated by renal function. Clinical context: IV infusion effects decay rapidly upon cessation due to redistribution and metabolism.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Glucose: primarily metabolized to CO2 and water; renal excretion negligible. Sodium: >90% renal. Potassium: ~90% renal, 10% fecal. Chloride: primarily renal.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte